Comparing the fixed combination brimonidine-timolol versus fixed combination dorzolamide-timolol in patients with elevated intraocular pressure^*

References

• Alward WL. Medical management of glaucoma. N Engl J Med 1998;339:1298–307
   PubMed Web of Science ®Google Scholar
• Stewart WC, Sharpe ED, Harbin TS Jr, et al. Brimonidine 0.2% versus dorzolamide 2% each given three times daily to reduce intraocular pressure. Am J Ophthalmol 2000;129: 723–7
   Google Scholar
• Francis BA, Du LT, Berke S, et al. Comparing the fixed combination dorzolamide-timolol (Cosopt) to concomitant administration of 2% dorzolamide (Trusopt) and 0.5% timolol – a randomized controlled trial and a replacement study. J Clin Pharm Ther 2004;29:375–80
   Google Scholar
• Hutzelmann J, Owens S, Shedden A, et al. Comparison of the safety and efficacy of the fixed combination of dorzolamide/ timolol and the concomitant administration of dorzolamide and timolol: a clinical equivalence study. International Clinical Equivalence Study Group. Br J Ophthalmol 1998;82:1249–53
   PubMed Web of Science ®Google Scholar
• Sall KN, Greff LJ, Johnson-Pratt LR, et al. Dorzolamide/timolol combination versus concomitant administration of brimonidine and timolol: six-month comparison of efficacy and tolerability. Ophthalmology 2003;110:615–24
   Google Scholar
• Zeyen T. Target pressures in glaucoma. Bull Sot Beige Ophtalmol 1999;274:61–5
   PubMedGoogle Scholar
• Alm A, Widengard I, Kjellgren D, et al. Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol. Br J Ophthalmol 1995;79:12–6
   PubMed Web of Science ®Google Scholar
• Kass MA, Hodapp E, Gordon M, et al. Part I. Patient administration of eyedrops: interview. Ann Ophthalmol 1982;14:775–9
   PubMed Web of Science ®Google Scholar
• Kass MA, Hodapp E, Gordon M, et al. Patient administration of eyedrops: observation. Part II. Ann Ophthalmol 1982;14: 889–93
   PubMed Web of Science ®Google Scholar
• Cvenkel B, Inar A. Ocular surface changes induced by topical antiglaucoma monotherapy. Ophthalmologica 2002;216:175–9
   PubMed Web of Science ®Google Scholar
• Noecker R. Effects of common ophthalmic preservatives on ocular health. Adv Ther 2001;18:205–15
   PubMed Web of Science ®Google Scholar
• Boyle JE, Ghosh K, Gieser DK, et al. A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide. Ophthalmology 1998;105:1945–51
   PubMed Web of Science ®Google Scholar
• Strahlman E, Tipping R, Vogel R, International Dorzolamide Study Group. A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol, and betaxolol. Arch Ophthalmol 1995;113: 1009–16
   Google Scholar
• Wilkerson M, Cyrlin M, Lippa EA, et al. Four-week safety and efficacy study of dorzolamide, a novel, active topical carbonic anhydrase inhibitor. Arch Ophthalmol 1993;111:1343–50
   PubMed Web of Science ®Google Scholar
• Rusk C, Sharpe E, Laurence J, et al. Dorzolamide Comparison Study Group. Comparison of the efficacy and safety of 2% dorzolamide and 0.5% betaxolol in the treatment of elevated intraocular pressure. Clin Ther 1998;20:454–66
   Google Scholar
• O’Donoghue EP, UK and Ireland Latanoprost Study Group. A comparison of latanoprost and dorzolamide in patients with glaucoma and ocular hypertension: a 3 month, randomised study. Br J Ophthalmol 2000;84: 579–82
   Google Scholar
• Araie M, Kitazawa Y, Azuma I, et al. The efficacy and safety of dose escalation of dorzolamide used in combination with other topical antiglaucoma agents. J Ocul Pharmacol Ther 2003;19:517–25
   PubMed Web of Science ®Google Scholar
• Sharpe ED, Day DG, Beischel CJ, et al. Brimonidine purite 0.15% versus dorzolamide 2% each given twice daily to reduce intraocular pressure in subjects with open angle glaucoma or ocular hypertension. Br J Ophthalmol 2004;88:953–6
   Google Scholar
• Kampik A, Arias-Puente A, O’Brart DP, et al. Intraocular pressure-lowering effects of latanoprost and brimonidine therapy in patients with open-angle glaucoma or ocular hypertension: a randomized observer-masked multicenter study. J Glaucoma 2002;11:90–6
   PubMed Web of Science ®Google Scholar
• Schuman JS. Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension. Surv Ophthalmol 1996;41(Suppl):S27–37
   Google Scholar
• DuBiner HB, Mroz M, Shapiro AM, et al. Brimonidine vs. Latanoprost Study Group. A comparison of the efficacy and tolerability of brimonidine and latanoprost in adults with open-angle glaucoma or ocular hypertension: a three-month, multi-center, randomized, double-masked, parallel-group trial. Clin Ther 2001;23:1969–83
   Google Scholar
• Walters TR. Development and use of brimonidine in treating acute and chronic elevations of intraocular pressure: a review of safety, efficacy, dose response, and dosing studies. Surv Ophthalmol 1996;41(Suppl):S19–26
   Google Scholar
• Nordland JR, Pasaquale LR, Robin AL, et al. The cardiovascular, pulmonary, and ocular hypotensive effects of 0.2% brimonidine. Arch Ophthalmol 1995;113:77–83
   PubMed Web of Science ®Google Scholar
• Whitson JT, Henry C, Hughes B, et al. Comparison of the safety and efficacy of dorzolamide 2% and brimonidine 0.2% in patients with glaucoma or ocular hypertension. J Glaucoma 2004;13:168–73
   PubMed Web of Science ®Google Scholar
• Wang RF, Serle JB, Gagliuso DJ, et al. Comparison of the ocular hypotensive effect of brimonidine, dorzolamide, latanoprost, or artificial tears added to timolol in glaucomatous monkey eyes. J Glaucoma 2000;9:458–62
   PubMed Web of Science ®Google Scholar
• Carrasco Font C, Arias Puente A, Garcia Saenz MC, et al. Efficiency of brimonidine 0.2% and dorzolamide 2% as adjunctive therapy to beta-blockers [in Spanish]. Arch Soc Esp Oftalmol 2004;79:163–8
   Google Scholar
• Strohmaier K, Snyder E, DuBiner H, et al. The efficacy and safety of the dorzolamide-timolol combination versus the concomitant administration of its components. Ophthalmology 1999;106(Suppl):1–9
   Google Scholar
• Craven ER, Walters TR, Williams R, et al. Brimonidine and timolol fixed-combination therapy versus monotherapy: a 3-month randomized trial in patients with glaucoma or ocular hypertension. J Ocul Pharmacol Ther 2005;21:337–48
   PubMed Web of Science ®Google Scholar
• Goñi FJ. The Brimonidine/Timolol Fixed Combination Study Group. 12-week study comparing the fixed combination of brimonidine and timolol with concomitant use of the individual components in patients with glaucoma and ocular hypertension. Eur J Ophthalmol 2005;15: 581–90
   Google Scholar
• Solish AM, DeLucca PT, Cassel DA, et al. Dorzolamide/timolol fixed combination versus concomitant administration of brimonidine and timolol in patients with elevated intraocular pressure: a 3-month comparison of efficacy, tolerability, and patient-reported measures. J Glaucoma 2004;13:149–57
   PubMed Web of Science ®Google Scholar